Logo Logo
Hilfe
Hilfe
Switch Language to English

Compera, Denise; Priglinger, Siegfried und Schumann, Ricarda Gisela (2019): Wirkungen und Nebenwirkungen von Ocriplasmin – ein Update. In: Klinische Monatsblatter für Augenheilkunde, Bd. 236, Nr. 6: S. 791-797

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Pharmacological vitreolysis with ocriplasmin is an effective treatment option for eyes with vitreomacular traction. Pre-marketing and post-marketing clinical studies revealed an improvement of visual function in ocriplasmin treated eyes and showed a release of traction in up to 78% of cases. Treatment success is related to patient selection based on positive predictive factors. Adverse events, such as visual acuity loss, dyschromatopsia or photopsia are known to be self-limited in the majority of eyes. Structural outer retinal layer changes, such as ellipsoid zone disturbances or subretinal fluid accumulation on SD-OCT analysis, as well as ERG abnormalities, are transient and correlated to VMT release. Surgical outcomes in patients with a prior history of ocriplasmin injection have been shown to be comparable with patients who proceeded directly to surgery without ocriplasmin treatment.

Dokument bearbeiten Dokument bearbeiten